Unveiling the Remarkable Results of CNM-Au8®: Clene Presents MS and ALS Data at 2023 AAN Annual Meeting

Clene Nanomedicine, Inc., a revolutionary clinical-stage biopharmaceutical company wholly owned by Clene Inc. (NASDAQ: CLNN), is proud to announce three presentations at the upcoming 2023 American Academy of Neurology (AAN) Annual Meeting in Boston, MA.

The platform presentations and poster will showcase the remarkable results of three clinical trials that demonstrate the effectiveness and safety of CNM-Au8® in the treatment of neurodegenerative diseases. Don’t miss this incredible opportunity to learn more about this groundbreaking technology!

About CNM-Au8®

CNM-Au8 is a revolutionary oral suspension of gold nanocrystals that can restore neuronal health and function! This incredible product catalyzes key energy-producing reactions, boosting neuronal and glial resilience to disease-related stressors.

Thanks to CNM-Au8®, you can enjoy increased energy production and utilization for optimum results. This remarkable product is proudly protected by a federally registered trademark of Clene Nanomedicine, Inc.

About Clene

Clene, a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, is on a mission to revolutionize the treatment of neurodegenerative diseases by targeting energetic failure – a groundbreaking approach that has the potential to revolutionize the way we treat these debilitating conditions.

With research and manufacturing operations in Maryland, Clene is leading the way in the development of innovative therapies that could improve the lives of those affected by neurodegenerative diseases.

Leave a Comment